SEARCH

SEARCH BY CITATION

References

  • Bertina, R.M., Koeleman, B.P.C., Koster, T., Rosendaal, F.R., Dirven, R.J., De Ronde, H., Van der Velden, P.A. & Reitsma, P.H. (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369, 6467.
  • Bloemenkamp, K.W.M., Rosendaal, F.R., Helmerhorst, F.M., Büller, H.R. & Vandenbroucke, J.P. (1995) Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing third generation progestagen. Lancet, 346, 15931596.
  • Cumming, A.M., Tait, R.C., Fildes, S., Yoong, A., Keeney, S. & Hay, C.R.M. (1995) Development of resistance to activated protein C during pregnancy. British Journal of Haematology, 90, 725727.
  • Curvers, J., Thomassen, M.C.L.G.D., Nicolaes, G.A.F., Van Oerle, R., Hamulyak, K., Hemker, H.C., Tans, G. & Rosing, J. (1999) Acquired APC resistance and oral contraceptives: differences between two functional tests. British Journal of Haematology, 105, 8894.
  • Curvers, J., Christella, M., Thomassen, L.G., De Ronde, H., Bertina, R.M., Rosendaal, F.R., Tans, G. & Rosing, J. (2002) Effects of (pre-) analytical variables on activated protein C resistance determined via a thrombin generation-based assay. Thrombosis and Haemostasis, 87, 483492.
  • Dahlbäck, B., Carlsson, M. & Svensson, P.J. (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proceedings of the National Academy of Sciences of the United States of America, 90, 10041008.
  • Greaves, M. & Preston, F.E. (2001) Rebuttal to: oral contraceptives and venous thromboembolism. Thrombosis and Haemostasis, 85, 932936.
  • Greengard, J.S., Sun, X., Xu, X., Fernandez, J.A., Griffin, J.H. & Evatt, B. (1994) Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet, 343, 13611362.
  • Heinemann, L.A.J., Spitzer, W.O. & Winkler, U.H. (1998a) Scientific problems with a noncausal artifact. American Journal of Obstetrics and Gynecology, 178, 11051106.
  • Heinemann, L.A.J., Assmann, A., Spannagl, M., Schramm, W., Dick, A., Kluft, C. & De Maat, M.P.M. (1998b) Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception, 58, 321322.
  • Jick, H., Jick, S.S., Gurewich, V., Myers, M.W. & Vasilakis, C. (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet, 346, 15891593.
  • Kluft, C. (2001) A rebuttal: oral contraceptives and venous thrombosis: reply. Thrombosis and Haemostasis, 85, 934936.
  • Koster, T., Rosendaal, F.R., De Ronde, H., Briet, E., Vandenbroucke, J.P. & Bertina, R.M. (1993) Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden Thrombophilia Study. Lancet, 342, 15031506.
  • Lidegaard, O. & Milsom, I. (1997) Oral contraceptives and venous thromboembolism. Lancet, 349, 16211623.
  • Meinardi, J.R., Henkens, C.M.A., Heringa, M.P. & Van Der Meer, J. (1997) Acquired APC resistance related to oral contraceptives and pregnancy and its possible implications for clinical practice. Blood Coagulation and Fibrinolysis, 8, 152154.
  • Nicolaes, G.A.F., Tans, G., Thomassen, M.C.L.G.D., Hemker, H.C., Pabinger, I., Varadi, K., Schwarz, H.P. & Rosing, J. (1995) Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. Journal of Biological Chemistry, 270, 2115821166.
  • Nicolaes, G.A.F., Thomassen, M.C.L.G.D., Tans, G., Rosing, J. & Hemker, H.C. (1997) Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coagulation and Fibrinolysis, 8, 2838.
  • Olivieri, O., Friso, S., Manzato, F., Guella, A., Bernardi, F., Lunghi, B., Girelli, D., Azzini, M., Brocco, G., Russo, C. & Corrocher, R. (1995) Resistance to activated protein C in healthy women taking oral contraceptives. British Journal of Haematology, 91, 465470.
  • Rodeghiero, F. & Tosetto, A. (1999) Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Annals of Internal Medicine, 130, 643650.
  • De Ronde, H. & Bertina, R.M. (1994) Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thrombosis and Haemostasis, 72, 880886.
  • Rosing, J., Tans, G., Nicolaes, G.A.F., Thomassen, M.C.L.G.D., Van Oerle, R., Van Der Ploeg, P.M.E.N., Heijnen, P., Hamulyak, K. & Hemker, H.C. (1997) Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. British Journal of Haematology, 97, 233238.
  • Rosing, J., Middeldorp, S., Curvers, J., Christella, M., Thomassen, L.G., Nicolaes, G.A., Meijers, J.C., Bouma, B.N., Büller, H.R., Prins, M.H. & Tans, G. (1999) Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet, 354, 20362040.
  • Spitzer, W.O. (1997) The 1995 pill scare revisited: anatomy of a non-epidemic. Human Reproduction, 12, 23472357.
  • Spitzer, W.O. (1998) Bias versus causality: interpreting recent evidence of oral contraceptive studies. American Journal of Obstetrics and Gynecology, 179, s43s50.
  • Thomassen, M.C.L.G.D., Curvers, J., Rimmer, J.E., Preston, F.E., Van Wersch, J.W.J., Tans, G. & Rosing, J. (1999) Influence of hormone replacement therapy, oral contraceptives and pregnancy on APC-resistance. Thrombosis and Haemostasis, Supplement, 82, 770771 .
  • Vandenbroucke, J.P. & Rosendaal, F.R. (1997) End of the line for ‘third-generation-pill’ controversy? Lancet, 349, 11131114.
  • Vandenbroucke, J.P., Helmerhorst, F.M., Bloemenkamp, K.W.M. & Rosendaal, F.R. (1997) Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. American Journal of Obstetrics and Gynecology, 177, 887891.
  • De Visser, M.C. (2003) Activated Protein C Resistance in the Absence of Factor V Leiden: Causes and Thrombosis Risk. PhD Thesis. Leiden University Medical Center, Leiden.
  • De Visser, M.C., Rosendaal, F.R. & Bertina, R.M. (1999) A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood, 93, 12711276.
  • Voorberg, J., Roelse, J., Koopman, R., Büller, H., Berends, F., Ten Cate, J.W., Mertens, K. & Van Mourik, J.A. (1994) Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet, 343, 15351536.
  • Winkler, U.H. (1998) Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review. American Journal of Obstetrics and Gynecology, 179, s51s61.
  • Winkler, U.H. (2000) Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism. Contraception, 62, 11s20s; discussion 37s–38s.
  • Woolf, B. (1955) On estimating the relation between blood group and disease. American Journal of Human Genetics, 19, 251.
  • World Health Organization (1995) Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet, 346, 15821588.
  • Zöller, B., Svensson, P.J., He, X. & Dahlbäck, B. (1994) Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. Journal of Clinical Investigation, 94, 25212524.